<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00317486</url>
  </required_header>
  <id_info>
    <org_study_id>AC-052-405</org_study_id>
    <nct_id>NCT00317486</nct_id>
  </id_info>
  <brief_title>Effects of Tracleer (Bosentan) on Pulmonary Arterial Hypertension Related to Eisenmenger Physiology</brief_title>
  <official_title>A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of Tracleer (Bosentan) on Oxygen Saturation and Cardiac Hemodynamics in Patients With Pulmonary Arterial Hypertension Related to Eisenmenger Physiology</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Actelion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Actelion</source>
  <brief_summary>
    <textblock>
      This study evaluates the effects of bosentan on oxygen saturation, hemodynamics and exercise&#xD;
      capacity in patients with pulmonary arterial hypertension related to Eisenmenger physiology.&#xD;
      Patients receive bosentan or placebo for 16 weeks.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2003</start_date>
  <completion_date type="Actual">April 2005</completion_date>
  <primary_completion_date type="Actual">April 2005</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline to Week 16 in oxygen saturation at rest with room air</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline to Week 16 in indexed pulmonary vascular resistance</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline to Week 16 in cardiac hemodynamics</measure>
  </secondary_outcome>
  <enrollment type="Actual">54</enrollment>
  <condition>Pulmonary Arterial Hypertension Related to Eisenmenger Physiology</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bosentan</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female patients at least 12 years with a body weight at least 40 kg&#xD;
             (inclusive) and with a functional class III (1998 WHO classification).&#xD;
&#xD;
          2. Patients with pulmonary arterial hypertension related to Eisenmenger physiology&#xD;
             echocardiographically established as atrial septal defect at least 2 cm effective&#xD;
             diameter and/or ventricular septal defect at least 1 cm effective diameter; PAH&#xD;
             confirmed via cardiac catheterization: mean pulmonary arterial pressure &gt;25 mm Hg,&#xD;
             pulmonary capillary wedge pressure &lt;15 mm Hg and pulmonary vascular resistance &gt;3 mm&#xD;
             Hg/l/min.&#xD;
&#xD;
          3. Patients with documented oxygen saturation up to 90%, and &gt;70% (at rest, with room&#xD;
             air).&#xD;
&#xD;
          4. Patients able to perform a 6-minute walk test at least 150 m, and up to 450 m.&#xD;
&#xD;
          5. Patients stable for at least 3 months prior to screening.&#xD;
&#xD;
          6. Bosentan naïve patients.&#xD;
&#xD;
          7. Female patients who are surgically sterile, postmenopausal or have documented&#xD;
             infertility.&#xD;
&#xD;
          8. Female patients of childbearing potential using one of the following methods of&#xD;
             contraception: Barrier-type devices (e.g., condom, diaphragm) used ONLY in combination&#xD;
             with a spermicide. A double-barrier method is recommended; intrauterine devices&#xD;
             (IUDs); oral or implanted contraceptives, if used in combination with a barrier&#xD;
             method.&#xD;
&#xD;
          9. Patients providing written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant patients, nursing mothers.&#xD;
&#xD;
          2. Patients with left ventricular dysfunction (ejection fraction &lt;40%).&#xD;
&#xD;
          3. Patients with restrictive lung disease (TLC&lt;70% predicted); obstructive lung disease&#xD;
             (FEV1&lt;70% predicted, with FEV1/FVC&lt;60%)&#xD;
&#xD;
          4. Patients with systolic blood pressure &lt; 85 mm Hg.&#xD;
&#xD;
          5. Patients with other conditions that may affect the ability to perform a 6-minute walk&#xD;
             test.&#xD;
&#xD;
          6. Patients unable to provide informed consent and comply with the patient protocol.&#xD;
&#xD;
          7. Patients with known coronary arterial disease.&#xD;
&#xD;
          8. Patients with serum creatinine &gt;125 µM/l.&#xD;
&#xD;
          9. Patients with iron deficiency (serum ferritin &lt;10 ng/ml) unless corrected by iron&#xD;
             supplement.&#xD;
&#xD;
         10. Patients with hemoglobin or hematocrit that is more than 30% below the normal range&#xD;
             (patients with secondary polycythemia are permitted).&#xD;
&#xD;
         11. Patients with AST and/or ALT values greater than 3 times the upper limit of normal.&#xD;
&#xD;
         12. Patients who have started or stopped treatment for PAH within one month of screening,&#xD;
             excluding anticoagulation.&#xD;
&#xD;
         13. Patients who are receiving glyburide (glibenclamide), cyclosporine A or tacrolimus at&#xD;
             inclusion or are expected to receive any of these drugs during the study.&#xD;
&#xD;
         14. Patients who are receiving vasodilators including, but not limited to epoprostenol or&#xD;
             prostacyclin analogues, or are expected to receive any of these drugs during the&#xD;
             study.&#xD;
&#xD;
         15. Patients active on organ transplant lists.&#xD;
&#xD;
         16. Patients taking phosphodiesterase inhibitors or endothelin receptor antagonists (other&#xD;
             than bosentan) or any other investigational drugs/devices.&#xD;
&#xD;
         17. Patients with planned surgical intervention during the study period.&#xD;
&#xD;
         18. Cardiac catheterization-specific exclusion criteria:&#xD;
&#xD;
               1. Patients who cannot safely have catheterization performed as indicated.&#xD;
&#xD;
               2. Patients in whom shunting is not at the atrial or ventricular level.&#xD;
&#xD;
               3. Patients with nonequal pulmonary venous desaturation that theoretically cannot be&#xD;
                  corrected with administration of 100% non-rebreather-supplied oxygen.&#xD;
&#xD;
               4. Patients with nonpulsatile pulmonary blood flow, or with multiple sources of&#xD;
                  pulmonary blood flow.&#xD;
&#xD;
               5. Patients with discontinuous pulmonary arteries, peripheral pulmonary arterial or&#xD;
                  venous stenosis &gt; 25% size of native PA or creating unequal bilateral PA mean&#xD;
                  pressures, PA band with gradient &gt; 20 mm Hg, tetralogy of fallot/pulmonary&#xD;
                  atresia, VSD/pulmonary atresia, DORV/pulmonary atresia, truncus arteriosus,&#xD;
                  scimitar syndrome.&#xD;
&#xD;
               6. Patients where SVC sampling cannot be performed, or where SVC sampling may be&#xD;
                  contaminated&#xD;
&#xD;
               7. Patients with ductus arteriosus.&#xD;
&#xD;
               8. Patients with mitral or pulmonary venous stenosis, intracavitary LV outflow&#xD;
                  obstruction, sub, valvar or supravalvar aortic stenosis or aortic coarctation.&#xD;
&#xD;
               9. Patients with &lt;10 indexed Wood units, greater than moderate mitral regurgitation,&#xD;
                  mean pulmonary venous pressure &gt; 16 mm Hg, pulmonary venous &quot;v&quot; waves &gt; 20 mm Hg,&#xD;
                  systemic ventricular end-diastolic pressure &gt; 16 mm Hg; patients with recognized&#xD;
                  extracardiac systemic venous collaterals to the pulmonary venous circulation,&#xD;
                  patients with recognized hepatic wedge pressure-inferior vena cava pressure&#xD;
                  gradient &gt; 12 mm Hg.&#xD;
&#xD;
              10. Patients (during catheterization) with uncorrectable hypercarbia with pCO2 &gt;55 mm&#xD;
                  Hg; patients with uncorrectable acidemia with pH &lt;7.34; patients in active pain&#xD;
                  or distress; unconscious or mechanically ventilated patients; patients with&#xD;
                  unstable systemic or pulmonary blood flow; systemic arterial or pulmonary artery&#xD;
                  pressures or hematocrit (change of &gt; 25% during catheterization); unstable&#xD;
                  cardiac rhythm dissimilar to baseline cardiac rhythm during physical examination&#xD;
                  assessments for the entire duration of the catheterization excepting nonsustained&#xD;
                  arrhythmia; patients with documented or recognized air embolism, hemorrhage,&#xD;
                  cardiac, cerebral or peripheral organ ischemia occurring during or immediately&#xD;
                  preceding the catheterization.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>BACH Pulmonary Hypertension Service</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-2303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Prince Alfred Hospital - Central Clinical School</name>
      <address>
        <city>Camperdown</city>
        <zip>NSW 2050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Royal Melbourne Hospital</name>
      <address>
        <city>Victoria</city>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum fur Innere Medizin II</name>
      <address>
        <city>Wien</city>
        <zip>AT-1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>BE-3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Peter Lougheed Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T1Y 6J4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Necker-Enfants Malades</name>
      <address>
        <city>Paris</city>
        <zip>75007</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herzzentrum NRW</name>
      <address>
        <city>Bad Oeynhausen</city>
        <zip>D-32545</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deutsches Herzzentrum Munchen</name>
      <address>
        <city>Munchen</city>
        <zip>D-80636</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Bologna</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Matteo Hospital</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academisch Ziekenhuis Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unidad Medico Quirurgica de Cardiologia - Edificio General</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scottish Vascular Unit - Western Infirmary</name>
      <address>
        <city>Glasgow</city>
        <zip>G11 6NT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Brompton Hospital</name>
      <address>
        <city>London</city>
        <zip>SW3 6NP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2010</verification_date>
  <study_first_submitted>April 21, 2006</study_first_submitted>
  <study_first_submitted_qc>April 21, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2006</study_first_posted>
  <disposition_first_submitted>February 11, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>February 11, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">February 15, 2010</disposition_first_posted>
  <last_update_submitted>February 11, 2010</last_update_submitted>
  <last_update_submitted_qc>February 11, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 15, 2010</last_update_posted>
  <keyword>pulmonary arterial hypertension</keyword>
  <keyword>Eisenmenger physiology</keyword>
  <keyword>bosentan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Arterial Hypertension</mesh_term>
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Eisenmenger Complex</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bosentan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

